Alleviation of skin lesions and bone pain in patients with SAPHO after tonsillectomy

Abstract

Abstract: Objective To evaluate the clinical efficacy of tonsillectomy on skin lesions and bone pain in patients with synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO). Methods Patients with SAPHO who were refractory to conservative treatment and then received tonsillectomy were recruited. The skin lesions were evaluated using palmoplantar pustulosis area and severity index (PPPASI) scoring. The pain was evaluated by the visual analog score (VAS). The scores of PPPASI and VAS at various follow-ups were recorded. Results Forty-four patients (36 women and 8 men) with a median age of 37.3 years were enrolled. One month after tonsillectomy, skin lesions and bone pain disappeared in 10% and 28% respectively. The disappearance rates 12-month post-op, were 62% and 77% respectively. Conclusions Tonsillectomy exhibits inhibition to skin lesions and bone pain in the patients with SAPHO. Tonsillectomy is a potential alternative treatment for the refractory cases.

Key words: SAPHO, tonsillectomy, palmoplantar pustulosis, bone pain, efficacy

CLC Number:

R593.9

WANG Yi, XIANG Yi-rong, LI Chen, ZHANG Wen, GAO Zhi-qiang. Alleviation of skin lesions and bone pain in patients with SAPHO after tonsillectomy[J]. Basic & Clinical Medicine, 2020, 40(12): 1671-1676.

References

[1] Chamot AM, Benhamou CL, Kahn MF, et al. Acne-pustulosis-hyperostosis-osteitis syndrome: results of a national survey 85 cases[J]. Rev Rheum Mal Osteoartic,1987,54:187-196.
[2] Kahn MF, Khan MA.The SAPHO syndrome[J]. Bailliere's Clin Rheumatol,1994, 8:333-362.
[3] Bhushan M, Burden AD, McElhone K, et al. Oral liarozole in the treatment of palmoplantar pustular psoria-sis: a randomized, double-blind, placebo-controlled study[J]. Br J Dermatol,2001, 145:546-553.
[4] Li C, Zuo Y, Wu N, et al. Synovitis, acne, pustulosis, hyperostosis and osteitis syndrome:a single centre study of a cohort of 164 patients[J]. Rheumatology (Oxford), 2016, 55: 1023-1030.
[5] Colina M, Govoni M, Orzincolo C, et al. Clinical and radiologic evolution of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a single center study of a cohort of 71 subjects[J]. Arthritis Rheum,2009, 61:813-821.
[6] 吴遐,李忱,李丽.SAPHO的皮肤表现及其进展[J].国际皮肤性病学杂志,2017,43:212-215.
[7] Li C, Wang L, Wu N, et al. A retrospective study of bone scintigraphy in the follow-up of patients with synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: Is it useful to repeat bone scintigraphy for disease assessment?[J]. Clin Rheumatol, 2020, 39:1305-1314.
[8] Assmann G, Simon P. The SAPHO syndrome—are microbes involved?[J].Best Pract Res Clin Rheumatol, 2011,25:423-434.
[9] Asmann G, Kueck O, Kirchhof T, et al.Efficacy of antibiotic therapy for SAPHO syndrome is lost after its discontinuation: aninterventional study[J]. Arthritis Res Ther,2009, 11:R140-147.
[10] Boutin RD, Resnick R. The SAPHO syndrome: an evolving concept for unifying several idiopathic disorders of bone and skin[J]. Am J Roentgenol,1998,170:585-591.
[11] Grosjean C, Hurtado-Nedelec M, Nicaise-Roland P, et al. Prevalence of autoantibodies in SAPHO syndrome: a single-center study of 90 patients[J]. J Rheumatol, 2010,37:639-643.
[12] Hurtado-Nedelec M, Chollet-Martin S, Nicaise-Roland P, et al.Characterization of the immune response in the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome[J]. Rheumatology, 2008,47:1160-1167.
[13] Hayem G, Hurtado-Nedelec M, Chollet-Martin S. The immune response in SAPHO syndrome: deficiency, hyper-responsiveness, or both?[J]. Curr Rheumatol Rev, 2013, 9:11-14.
[14] Firinu D, Barca MP, Lorrai MM, et al. TH17 cells are increased in the peripheral blood of patientswith SAPHO syndrome[J]. Autoimmunity, 2014, 47:389-394.
[15] Marzano AV, Ishak RS, Saibeni S, et al. Autoinflam-matory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet's syndrome: a comprehen-sive review and disease classification criteria[J]. Clin Rev Allergy Immunol, 2013, 45:202-210.
[16] Burgemeister LT, Baeten DL, Tas SW. Biologics for rare inflammatory diseases: TNF blockade in the SAPHO syndrome[J]. Neth J Med, 2012, 70:444-449.
[17] 李忱,王景,史小虎,等.35例难治性SAPHO患者应用肿瘤坏死因子-α拮抗剂的治疗随访[J].临床荟萃,2016,31:45-47.
[18] Wu W, Debbaneh M, Moslehi H, et al. Tonsillectomy as a treatment for psoriasis: a review[J]. J Dermatolog Treat, 2014, 25: 482-486.
[19] Takahara M, Hirata Y, Nagato T, et al. Treatment outcome and prognostic factors of tonsillectomy for palmoplantar pustulosis and pustulotic arthro-osteitis: a retrospective subjective and objective quantitative analysis of 138 patients[J]. J Dermatol, 2018,45:812-823.
[20] Ono T, Jono M, Kito M, et al. Evaluation of tonsillectomy as a treatment for pustulosis palmaris et plantaris[J]. Acta Otolaryngol Suppl, 1983,401:12-16.